Shares of ORIC Pharmaceuticals (ORIC) surged more than 20% in the pre-market hours today after announcing potentially best-in-class preliminary efficacy and safety data from the ongoing early-stage study of its novel, once-daily candidate, ORIC-944, for prostate cancer. ORIC-944, in combination with AR inhibitors, J&J’s (JNJ) Erleada (apalutamide) and Bayer’s (BAYRY) Nubeqa (darolutamide), is being evaluated in the phase Ib study for treating patients with metastatic castration-resistant prostate cancer (mC ...